Immunocore presented two posters at CROI 2024
2024年3月6日 - 6:30AM
Immunocore presented two posters at CROI
2024
Preclinical data highlights importance of TCR
biology in development of new HIV treatments
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn.
& ROCKVILLE, Md., US, 05 March 2024) Immunocore Holdings plc
(Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage
biotechnology company pioneering and delivering transformative
immunomodulating medicines to radically improve outcomes for
patients with cancer, infectious diseases and autoimmune diseases,
presented two posters at the 2024 Conference on Retroviruses and
Opportunistic Infections (CROI).
Poster details
Title: Labelled high affinity TCRs for
detection of HIV epitopes on infected cells: How low can we go?
Presenting author: Zoe
WallaceSession: Immune pressure on HIV reservoirs
– Poster session-D6Date & time: 4 March 2024,
14:30-16:00 MST
Title: Instability of the HLA-E peptidome of
HIV presents a major barrier to therapeutic targeting
Presenting author: Zoe
WallaceSession: HIV immunotherapy and
immunoprophylaxis – Poster session-C5Date &
time: 5 March 2024, 14:30-16:00 MST
##
About ImmTAV molecules and infectious
diseasesImmTAV (Immune mobilising monoclonal TCRs Against
Virus) molecules are novel bispecifics that, like ImmTAC (Immune
mobilising monoclonal TCRs Against Cancer) molecules, are designed
to enable the immune system to recognize and eliminate virally
infected cells.
Immunocore is advancing clinical candidates to
cure patients with human immunodeficiency virus (HIV) and hepatitis
B virus (HBV). The Company aims to achieve sustained control of HIV
after people living with HIV stop anti-retroviral therapy (ART),
without the risk of virological relapse or onward transmission.
This is known as ‘functional cure’. For the treatment of HBV, the
Company aims to achieve sustained loss of circulating viral
antigens and markers of viral replication after stopping medication
for people living with chronic HBV.
About ImmunocoreImmunocore is a
commercial-stage biotechnology company pioneering the development
of a novel class of TCR bispecific immunotherapies called ImmTAX –
Immune mobilizing monoclonal TCRs Against X disease – designed to
treat a broad range of diseases, including cancer, autoimmune, and
infectious disease. Leveraging its proprietary, flexible,
off-the-shelf ImmTAX platform, Immunocore is developing a deep
pipeline in multiple therapeutic areas, including five clinical
stage programs in oncology and infectious disease, advanced
pre-clinical programs in autoimmune disease and multiple earlier
pre-clinical programs. The Company’s most advanced oncology TCR
therapeutic, KIMMTRAK has been approved for the treatment of
HLA-A*02:01-positive adult patients with unresectable or metastatic
uveal melanoma in the United States, European Union, Canada,
Australia, and the United Kingdom.
CONTACT: Immunocore
Sébastien Desprez, Head of CommunicationsT: +44 (0) 7458030732E:
sebastien.desprez@immunocore.comFollow on Twitter: @Immunocore
Investor Relations Clayton Robertson,
Head of Investor RelationsT: +1 215-384-4781E:
ir@immunocore.com
Immunocore (NASDAQ:IMCR)
過去 株価チャート
から 1 2025 まで 2 2025
Immunocore (NASDAQ:IMCR)
過去 株価チャート
から 2 2024 まで 2 2025